Gennex Laboratories Ltd

On 21-Nov, Gennex Laboratories Ltd witnessed a notable decline in its share price, falling by 4.79% to close at ₹13.73. This drop reflects a continuation of recent downward momentum amid subdued investor interest and underperformance relative to broader market benchmarks.

As of 17-Nov, Gennex Laboratories Ltd's stock price is 15.05, down 4.51%, and has significantly underperformed its sector and the Sensex over the past year. The decline in investor participation and inability to maintain momentum suggest a lack of confidence in the company's prospects.

Gennex Lab has demonstrated significant growth in net sales and profitability, with net sales increasing from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, and profit after tax rising from 1.86 Cr to 18.12 Cr in the same period, despite rising raw material costs and negative cash flow in recent years. Total assets grew from 56.94 Cr to 255.86 Cr, indicating strong overall financial expansion.

Gennex Lab has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales increasing from 69.55 Cr to 137.90 Cr and profit after tax rising from 4.92 Cr to 18.12 Cr, despite rising raw material costs and negative cash flow in 2025. Total assets and liabilities both grew to 255.86 Cr during this period.

As of 12-Nov, Gennex Laboratories Ltd is currently experiencing a price increase to 15.96, with a notable rise of 1.66% recently. Despite strong short-term performance, the stock has seen a year-to-date decline of 2.33% and a significant drop in delivery volume, which may affect future trading activity.

As of 10-Nov, Gennex Laboratories Ltd is currently priced at 15.11, reflecting a 5.96% increase after a trend reversal. Despite a drop in investor participation, the stock has outperformed its sector today and has risen 23.95% over the past month, although it remains down year-to-date and over the past year.

As of November 7, 2025, Gennex Lab's valuation is considered attractive with a PE ratio of 19.66, favorable compared to peers like Sun Pharma and Divi's Lab, and despite recent underperformance, it has shown strong long-term growth of 296.11% over five years.

As of November 7, 2025, Gennex Lab. is considered fairly valued with a PE ratio of 19.66, lower than its peers Sun Pharma and Divi's Lab., and while it has underperformed the Sensex in the past year with a -32.10% return, it has achieved a substantial 296.11% return over the last five years.

As of November 7, 2025, Gennex Lab. is considered overvalued with a PE ratio of 19.66 and an attractive valuation grade, despite lower PE ratios than some peers like Sun Pharma and Divi's Lab., but higher than Cipla and Dr. Reddy's Labs, and has underperformed with a year-to-date return of -12.73% compared to the Sensex's 6.50%.

As of November 6, 2025, Gennex Lab. is rated very attractive and undervalued with a PE ratio of 19.73 and strong long-term growth potential, despite a recent 33.84% decline in stock performance.

The next results date for Gennex Lab. is 14 November 2025.

As of 06-Nov, Gennex Laboratories Ltd's stock price is declining at 14.31, down 5.29% today and 12.9% over the last three days. The stock has significantly underperformed compared to the Sensex and shows negative investor sentiment despite strong long-term returns.

As of November 3, 2025, Gennex Lab. is considered undervalued with a PE ratio of 21.32 and favorable comparisons to peers, despite recent stock declines, while showing strong long-term growth potential with a 150.97% return over three years.

As of 03-Nov, Gennex Laboratories Ltd's stock price is at 15.46, down 5.9%, with significant declines in both delivery volume and year-over-year performance. The company's low return on equity and reliance on non-operating income contribute to its underperformance compared to the broader market.

As of 27-Oct, Gennex Laboratories Ltd is currently valued at Rs 16.35, reflecting an 11.91% increase and strong performance, outperforming its sector and the benchmark Sensex significantly over the past week and month. The stock shows positive momentum with rising investor interest and consistent gains over the last five days.

As of October 27, 2025, Gennex Lab's valuation has shifted to fair, with a PE ratio of 22.54, indicating it is fairly valued compared to peers, having outperformed the Sensex over three years but underperformed in the last year.

As of 15-Oct, Gennex Laboratories Ltd is experiencing a price increase to 13.93, reflecting a 5.53% rise, with strong recent performance and significant investor participation. Despite a year-to-date decline of 14.75%, the stock has outperformed the Sensex in the short term.